What's New

Last Posted: Mar 10, 2023

• A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension.
  Michail Mamalakis et al. Scientific reports 2023 13(1) 3812
• Development and validation of a respiratory-responsive vocal biomarker-based tool for generalizable detection of respiratory impairment: independent case-control studies in multiple respiratory conditions including asthma, chronic obstructive pulmonary disease, and COVID-19.
  Savneet Kaur et al. Journal of medical Internet research 2023
• Research Progress of Respiratory Disease and Idiopathic Pulmonary Fibrosis Based on Artificial Intelligence.
  Gerui Zhang et al. Diagnostics (Basel, Switzerland) 2023 13(3)
• Use of big data on the social determinants of TB to find the "missing millions".
  Biermann O et al. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 26(12) 1194-1196
• Perceptions of airway gene therapy for cystic fibrosis.
  Donnelley Martin et al. Expert opinion on biological therapy 2022
• Gene therapy for cystic fibrosis: Challenges and prospects.
  Sui Hongshu et al. Frontiers in pharmacology 2022 131015926
• Effect of Physical Activity Program on the Quality of Life of Children with Cystic Fibrosis at School Age: A Randomized Clinical Trail.
  Hakim Ashrafalsadat et al. Tanaffos 2022 21(1) 63-69
• Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.
  Onishchenko Dmytro et al. Nature medicine 2022
• Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population.
  Liu Qing et al. BMC pulmonary medicine 2022 22(1) 327
• The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study.
  Cameli Paolo et al. Biomedicines 2022 10(8)

More